Overview of Available Third-Line Options in mCRC
Panelists discuss how available third-line therapies, such as FTD/TPI, regorafenib, and others, are chosen based on survival data, safety, and patient quality of life.
The therapeutic landscape for metastatic colorectal cancer once patients progress to third-line treatment is outlined, including available agents, such as trifluridine/tipiracil (FTD/TPI), regorafenib, and newer targeted therapies.
The RECOURSE trial plays a central role in establishing FTD/TPI as a viable option, with its demonstrated improvements in overall survival and a manageable safety profile.
Clinicians highlight how such data provide confidence in recommending therapy beyond standard second-line regimens, stressing that treatment choice must balance efficacy with tolerability to ensure quality of life for patients already heavily pretreated.
Author's summary: Experts discuss third-line treatment options for mCRC.
More News
- Marvin Vettori's Comeback: Aiming to End His Three-Fight Skid at UFC 323
- Newcastle 2-1 Burnley: Scott Parker post-match interview
- Scott Parker's 'polar opposite' Newcastle United verdict
- Newcastle 2-1 Burnley: What Parker said
- Durham Council Delays Major Development at Former Police Headquarters
- Time to talk about Bruno! Brunno Ferreira defeats Marvin Vettori by Unanimous Decision
- Durham Osteopathy Receives 2025 Consumer Choice Award
- Durham University
- Awareness walk held to commemorate INT'L Anti-Corruption Day
- North Little Rock maritime museum to commemorate anniversary of Pearl Harbor attack